Research Article
BibTex RIS Cite

LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ

Year 2020, Volume: 8 Issue: 1, 48 - 51, 20.04.2020

Mahmut Büyükşimşek , Mustafa Toğun Abdullah Evren Yetişir Cem Mirili , Ali Oğul , Mert Tohumcuoğlu Semra Paydaş

https://doi.org/10.37696/nkmj.632911

Abstract

Amaç: Kemoterapi sırasında
hepatit enfeksiyonu reaktivasyonu lenfoma hastalarında önemli bir sorundur.
Merkezimizde tedavi edilen lenfoma hastalarında hepatit B virüsü (HBV) ve
hepatit C virüsü (HCV) sıklığını araştırmayı amaçladık.



Materyal ve Metot: Merkezimizde
2012-2018 yılları arasında tedavi edilen non-hodgkin lenfoma (NHL) ve hodgkin
lenfoma (HL) hastalarının dosyaları retrospektif olarak incelendi. Hastaların
HBsAg, Anti-HBs, Anti-HBc ve Anti-HCV parametreleri değerlendirildi.



Bulgular: 240
NHL hastasının 21' inde (% 8.7) HBsAg antijeni pozitifti. 9 hastada (% 3.7)
Anti-HCV pozitifliği tespit edildi. 79 hastada (%33) HBsAg (-), Anti-HBs (+) ve
Anti-HBc (+) saptandı ve geçirilmiş hepatit B enfeksiyonu olarak değerlendirildi.
110 HL hastasının 10'unda (% 9,1) HBsAg (+), 3'ünde (% 2,7) Anti-HCV (+) ve
29'unda (% 26) Anti-HBc (+) tespit edildi.



Sonuç: Ülkemiz
verilerine göre HBV ve HCV pozitifliğinin yüksek olduğu belirlenmiştir. Bu,
hepatit enfeksiyonunun kendi başına lenfomaya neden olabileceği gerçeğinden
kaynaklanmış olabilir. Bölgemizdeki Hepatit B ve C pozitifliği önemli bir sorun
teşkil etmektedir. Aşılama ve korunma yöntemleri hakkında gerekli bilgiler
sağlanmalıdır.

Keywords

Lenfoma HBV HCV

References

  • Referans1 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN. 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: IARC; 2013.
  • Referans2 Alexander DD, Mink PJ, Adami H-O, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:1–39
  • Referans 3 De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
  • Referans 4 Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):130–44.
  • Referans 5 Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078–85.
  • Referans 6 Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013;37:1107–15.
  • Referans 7 Kim JH, Bang Y-J, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res. 2002;93:471–7.
  • Referans 8 Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica. 2004 Jan;89(1):70-6. Referans 9 Altıntaş A, Kaplan MA, Çil T, Yılmaz Ş, Bayan K, Danış R, et al. Hepatitis B virus infection in patient with Hodgkin’s and non-Hodgkin’s lymphoma and clinical significance. Int J Hematol. 2007, Vol 17, Num 1 Page(s): 001-006
  • Referans 10 Taborelli M, Polesel J, Montella M, Libra M, Tedeschi R, Battiston M, et al. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. Infect Agent Cancer. 2016 Jun 23;11:27. Referans 11 Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026.
  • Referans 12 Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270–5.
  • Referans 13 Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147–53.
  • Referans 14 Wursthorn K, Wedemeyer H, Manns MP. Managing HBV inpatients with impaired immunity. Gut. 2010;59:1430–45.
  • Referans 15 Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta- analysis. J Clin Virol. 2013;57:209–14.

Year 2020, Volume: 8 Issue: 1, 48 - 51, 20.04.2020

Mahmut Büyükşimşek , Mustafa Toğun Abdullah Evren Yetişir Cem Mirili , Ali Oğul , Mert Tohumcuoğlu Semra Paydaş

https://doi.org/10.37696/nkmj.632911

Abstract

References

  • Referans1 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN. 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: IARC; 2013.
  • Referans2 Alexander DD, Mink PJ, Adami H-O, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:1–39
  • Referans 3 De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
  • Referans 4 Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):130–44.
  • Referans 5 Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078–85.
  • Referans 6 Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013;37:1107–15.
  • Referans 7 Kim JH, Bang Y-J, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res. 2002;93:471–7.
  • Referans 8 Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica. 2004 Jan;89(1):70-6. Referans 9 Altıntaş A, Kaplan MA, Çil T, Yılmaz Ş, Bayan K, Danış R, et al. Hepatitis B virus infection in patient with Hodgkin’s and non-Hodgkin’s lymphoma and clinical significance. Int J Hematol. 2007, Vol 17, Num 1 Page(s): 001-006
  • Referans 10 Taborelli M, Polesel J, Montella M, Libra M, Tedeschi R, Battiston M, et al. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. Infect Agent Cancer. 2016 Jun 23;11:27. Referans 11 Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026.
  • Referans 12 Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270–5.
  • Referans 13 Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147–53.
  • Referans 14 Wursthorn K, Wedemeyer H, Manns MP. Managing HBV inpatients with impaired immunity. Gut. 2010;59:1430–45.
  • Referans 15 Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta- analysis. J Clin Virol. 2013;57:209–14.
There are 13 citations in total.

Details

Primary Language Turkish
Subjects Clinical Sciences
Journal Section Orginal Article
Authors

Mahmut Büyükşimşek 0000-0003-4886-7060

Mustafa Toğun This is me 0000-0003-0955-0781

Abdullah Evren Yetişir This is me 0000-0001-7214-8184

Cem Mirili 0000-0002-5986-5493

Ali Oğul 0000-0003-4886-7060

Mert Tohumcuoğlu This is me 0000-0003-3653-4429

Semra Paydaş 0000-0003-4642-3693

Publication Date April 20, 2020
Published in Issue Year 2020 Volume: 8 Issue: 1

Cite

APA Büyükşimşek, M., Toğun, M., Yetişir, A. E., Mirili, C., et al. (2020). LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ. Namık Kemal Tıp Dergisi, 8(1), 48-51. https://doi.org/10.37696/nkmj.632911
AMA Büyükşimşek M, Toğun M, Yetişir AE, Mirili C, Oğul A, Tohumcuoğlu M, Paydaş S. LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ. NKMJ. April 2020;8(1):48-51. doi:10.37696/nkmj.632911
Chicago Büyükşimşek, Mahmut, Mustafa Toğun, Abdullah Evren Yetişir, Cem Mirili, Ali Oğul, Mert Tohumcuoğlu, and Semra Paydaş. “LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ”. Namık Kemal Tıp Dergisi 8, no. 1 (April 2020): 48-51. https://doi.org/10.37696/nkmj.632911.
EndNote Büyükşimşek M, Toğun M, Yetişir AE, Mirili C, Oğul A, Tohumcuoğlu M, Paydaş S (April 1, 2020) LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ. Namık Kemal Tıp Dergisi 8 1 48–51.
IEEE M. Büyükşimşek, M. Toğun, A. E. Yetişir, C. Mirili, A. Oğul, M. Tohumcuoğlu, and S. Paydaş, “LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ”, NKMJ, vol. 8, no. 1, pp. 48–51, 2020, doi: 10.37696/nkmj.632911.
ISNAD Büyükşimşek, Mahmut et al. “LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ”. Namık Kemal Tıp Dergisi 8/1 (April 2020), 48-51. https://doi.org/10.37696/nkmj.632911.
JAMA Büyükşimşek M, Toğun M, Yetişir AE, Mirili C, Oğul A, Tohumcuoğlu M, Paydaş S. LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ. NKMJ. 2020;8:48–51.
MLA Büyükşimşek, Mahmut et al. “LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ”. Namık Kemal Tıp Dergisi, vol. 8, no. 1, 2020, pp. 48-51, doi:10.37696/nkmj.632911.
Vancouver Büyükşimşek M, Toğun M, Yetişir AE, Mirili C, Oğul A, Tohumcuoğlu M, Paydaş S. LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ. NKMJ. 2020;8(1):48-51.